0 213

Cited 6 times in

A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer

DC FieldValueLanguage
dc.contributor.author김혜련-
dc.contributor.author조병철-
dc.contributor.author허수진-
dc.contributor.author심효섭-
dc.contributor.author임선민-
dc.contributor.author정인경-
dc.date.accessioned2017-10-26T07:32:00Z-
dc.date.available2017-10-26T07:32:00Z-
dc.date.issued2016-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/152155-
dc.description.abstractOBJECTIVES: To evaluate whether the selection of first-line chemotherapy based on ERCC1 and RRM1 mRNA expression levels would improve clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: Eligible patients were randomly assigned 1:1 to the experimental and control arms; the experimental arm received gemcitabine/carboplatin (GC) if ERCC1 and RRM1 expression was low, gemcitabine/vinorelbine (GV) if ERCC1 was high and RRM1 was low, docetaxel/carboplatin (DC) if ERCC1 was low and RRM1 was high, and docetaxel/vinorelbine (DV) if both were high. In the control arm, patients received DC. RESULTS: This study was prematurely terminated after the futility analysis of 43 progression-free survival (PFS) events. A total of 55 patients (n = 26 in the experimental arm, n = 29 in the control arm) were evaluable for efficacy and toxicity. Nineteen (73.1%) patients were assigned to receive GC, 0 (0.0%) to GV, 4 (15.4%) to DC, and 3 (11.5%) to DV in the experimental arm. The overall response rates were 42.3 and 48.3% in the experimental and control arms, respectively, which were not statistically different (P = 0.657). The median PFS was 5.2 months in the experimental arm and 5.4 months in the control arm (P = 0.286). The median overall survival was 17.4 months in the experimental arm and 12.6 months in the control arm (P = 0.638). The occurrence of grade 3 or higher neutropenia (69.2 vs. 93.1%, P = 0.035) and febrile neutropenia (3.8 vs. 24.1%, P = 0.054) was more common in the control arm. CONCLUSION: ERCC1 and RRM1 mRNA expression-based chemotherapy did not improve clinical outcomes in advanced NSCLC (NCT01648517).-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer Verlag-
dc.relation.isPartOfCANCER CHEMOTHERAPY AND PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/pharmacology-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCarboplatin/administration & dosage-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/genetics-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology-
dc.subject.MESHDNA-Binding Proteins/genetics*-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/analogs & derivatives-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHEndonucleases/genetics*-
dc.subject.MESHFemale-
dc.subject.MESHGene Expression Regulation, Neoplastic-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy*-
dc.subject.MESHLung Neoplasms/genetics-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRNA, Messenger/metabolism-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTaxoids/administration & dosage-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTumor Suppressor Proteins/genetics*-
dc.subject.MESHVinblastine/administration & dosage-
dc.subject.MESHVinblastine/analogs & derivatives-
dc.subject.MESHYoung Adult-
dc.titleA randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer-
dc.typeArticle-
dc.publisher.locationGermany-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorSu Jin Heo-
dc.contributor.googleauthorInkyung Jung-
dc.contributor.googleauthorChoong-kun Lee-
dc.contributor.googleauthorJee Hung Kim-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorYong Wha Moon-
dc.contributor.googleauthorHyo Sup Shim-
dc.contributor.googleauthorJaeheon Jeong-
dc.contributor.googleauthorJoo-Hang Kim-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.1007/s00280-016-2968-z-
dc.contributor.localIdA03822-
dc.contributor.localIdA04355-
dc.contributor.localIdA02219-
dc.contributor.localIdA03369-
dc.contributor.localIdA03693-
dc.contributor.localIdA01166-
dc.relation.journalcodeJ00437-
dc.identifier.eissn1432-0843-
dc.identifier.pmid26811178-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs00280-016-2968-z-
dc.subject.keywordChemotherapy-
dc.subject.keywordERCC1-
dc.subject.keywordNon-small cell lung cancer-
dc.subject.keywordRRM1-
dc.subject.keywordmRNA expression-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameHeo, Su Jin-
dc.contributor.alternativeNameShim, Hyo Sup-
dc.contributor.alternativeNameLim, Sun Min-
dc.contributor.alternativeNameJung, In Kyung-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorHeo, Su Jin-
dc.contributor.affiliatedAuthorShim, Hyo Sup-
dc.contributor.affiliatedAuthorLim, Sun Min-
dc.contributor.affiliatedAuthorJung, In Kyung-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.citation.volume77-
dc.citation.number3-
dc.citation.startPage539-
dc.citation.endPage548-
dc.identifier.bibliographicCitationCANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.77(3) : 539-548, 2016-
dc.date.modified2017-10-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.